ALK chromosomal alterations in neuroendocrine tumors.

@article{Montagut2011ALKCA,
  title={ALK chromosomal alterations in neuroendocrine tumors.},
  author={Clara Montagut and E Arriola and Ana Bel{\'e}n Galv{\'a}n and Federico G. A. Rojo and M Luz Godino Salido and Manel Gall{\'e}n and Mar Garc{\'i}a and Alejandro Mart{\'i}nez and Françesca Pons and S{\`o}nia Servitja and Mar Iglesias and S{\'i}lvia Men{\'e}ndez and Sergio A. Serrano and Francesc Sol{\'e} and Ana Rovira and J 1137 Albanell and Joaquim Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={10585}
}
10585 Background: Neuroendocrine tumors (NETs) comprise a heterogeneous group of neoplasms containing biologically active peptides and amines in their cytoplasm. Anaplastic lymphoma kinase (ALK) translocation has recently emerged as a potent predictor of benefit for treatment with ALK inhibitors. The endpoint of this study was to analyze ALK translocations… CONTINUE READING